This one-day decline has now brought NVO’s twelve-month return to -56%. The pertinent question: Is this a buying opportunity?

Harding Loevner reports the International Small Companies Equity strategy rose 16.1% in 2025. Read the full report for more ...

Novo Nordisk A/S is rated a Strong Buy with robust free cash flow and high gross margins supporting valuation. Read more on NVO stock here.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products ...